Skin tightening cosmetic composition
By using the combination of ingredients such as glucosyl quinolate, micro HA and small HA in cosmetics, the problem that existing cosmetics are difficult to improve skin firmness and elasticity for a long time is solved, and significant skin improvement effects are achieved while avoiding the Skin irritation and sunlight sensitivity.
Patent Information
- Application Number
- CN202280092183.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-27
- Filing Date
- 2022-12-27
- Publication Date
- 2024-12-03
AI Technical Summary
Existing cosmetics are difficult to effectively improve skin firmness and elasticity in the long term, and may cause skin irritation or increase sensitivity to sunlight.
Using topical cosmetic compositions containing glucosyl pentagalate, micro HA and small HA, combined with other ingredients such as aminobutyric acid, low molecular weight hyaluronic acid, polyphenols and peptides, to form a stable skin barrier and enhance skin elasticity Protein production and water moisturizing ability to reduce wrinkles and roughness.
Significantly improve skin firmness, elasticity and hydration within 28 days to 56 days, reduce wrinkle depth and roughness, and do not cause skin irritation, providing long-lasting skin improvement effects.
Smart Images

Figure CN119072298A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 294,004, filed on December 27, 2021, which is incorporated herein by reference in its entirety. Background Art
[0003] Aging and exposure to environmental factors (such as ultraviolet light exposure from sunlight) can cause adverse changes in the appearance and physiology of the skin, such as the development of fine lines and wrinkles, loss of elasticity, increased sagging, and loss of skin firmness. Many cosmetic products are intended to tighten and firm the skin and / or reduce wrinkles, but typically such products achieve this effect by acting as effective moisturizers that temporarily reduce skin water loss and "plump" the skin, making fine lines and wrinkles look less noticeable. However, the effects of such products are minimal and short-lived, and do not significantly change the elasticity or firmness of the skin.
[0004] Products containing retinol can thicken the skin by inhibiting collagen breakdown and increasing the rate of skin cell turnover. However, such products usually need to be applied daily for 3-6 months before a noticeable difference in the skin is seen. In addition, retinol products may cause skin irritation and may make the skin sensitive to sun exposure.
[0005] Therefore, there is a need for new products that can be easily applied to the skin, do not cause skin irritation or sun sensitivity, and provide longer lasting improvements in skin firmness and elasticity. The cosmetic products of the present disclosure provide such improved properties. Summary of the invention
[0006] In various embodiments, the present disclosure is directed to topical compositions, particularly topical cosmetic compositions, comprising about 0.2 wt % to 0.6 wt % of glucosyl pentagallate, about 0.02 wt % to 0.07 wt % of micro HA, and about 0.05 wt % to 0.15 wt % of mini HA, in combination with one or more cosmetically acceptable excipients selected from the group consisting of UV protectants, emollients, moisturizers, antibacterial agents, and emulsifiers.
[0007] In other embodiments, the compositions of the present disclosure further comprise about 0.02% to 0.07% by weight of aminobutyric acid.
[0008] In various embodiments, the various compositions of the present disclosure described herein are applied to the epidermis of a subject at a rate of 1-10 g / cm per day. 2After at least 28 days, the epidermis has improved firmness, skin thickness, elasticity, increased hydration, reduced roughness, or decreased wrinkle depth.
[0009] The compositions of the present disclosure can be in any form suitable for cosmetic application, including serums, creams, lotions, and the like.
[0010] In a particular embodiment of the disclosed composition, such compounds include about 0.5 wt % glucosyl pentagallate, about 0.05 wt % aminobutyric acid, about 0.05 wt % micro-HA, and about 0.10 wt % small-HA. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1A : Absolute insoluble elastin concentration after 14 days; Figure 1B : Insoluble elastin along with total protein after 14 days.
[0012] Figure 2 : Average skin roughness after treatment with the neck firming cream of Example 1 before application (D0) and after 28 days (D28) and 56 days (D56).
[0013] Figure 3 : Percentage of volunteers showing improvement in average roughness 28 days (D28) and 56 days (D56) after application of the neck firming composition of Example 1.
[0014] Figure 4 : Improvement in firmness 28 days (D28) and 56 days (D56) after application of the neck firming composition of Example 1 compared to the control (vehicle only).
[0015] Figure 5 : Ultrasonic scan images of representative skin samples taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the neck firming composition of Example 1.
[0016] Figure 6 : High resolution images showing improvement in skin appearance taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the neck firming composition of Example 1.
[0017] Figure 7 : Wrinkle depth images showing reduction in wrinkle depth of a representative subject taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the neck firming composition of Example 1.
[0018] Figure 8: Subjective feelings of the subjects at 28 days (D28) and 56 days (D56) after using the neck firming composition of Example 1.
[0019] Fig. 9 : Average skin roughness at the beginning (D0) and after 28 days (D28) and 56 days (D56) of applying the eye cream of Example 2.
[0020] Fig.10 : Percentage of test subjects showing improvement in skin roughness 28 days (D28) or 56 days (D56) after application of the eye cream of Example 2.
[0021] Fig.11 : Skin density measured before treatment (D0) and 28 days (D28) and 56 days (D56) after application of the eye cream of Example 2.
[0022] Fig.12 : Percentage of subjects showing improvement in skin density 28 days (D28) and 56 days (D56) after application of the eye cream of Example 2.
[0023] Fig.13 : Average firmness values measured before application of the eye cream of Example 2 (D0) and after 28 days (D28) and 56 days (D56).
[0024] Fig.14 : Ultrasonic scanning images of representative skin samples taken before (D0) and after 28 days (D28) and 56 days (D56) of applying the eye cream composition of Example 2.
[0025] Fig.15 : High resolution images showing improvement in skin appearance taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the eye cream composition of Example 2.
[0026] Fig.16 : Wrinkle depth images showing reduction in wrinkle depth of a representative subject taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the eye cream composition of Example 2.
[0027] Fig.17 : Subjective feelings of the subjects at 28 days (D28) and 56 days (D56) after using the eye cream composition of Example 2.
[0028] Fig.18 : Average skin roughness after treatment with the night moisturizer composition of Example 3, before application (D0) and after 28 days (D28) and 56 days (D56).
[0029] Fig.19 : Percentage of test subjects showing improvement in skin roughness 28 days (D28) or 56 days (D56) after application of the nighttime moisturizer composition of Example 3.
[0030] Fig. 20 : Average melanin values of test subjects before application (D0) and 28 days (D28) or 56 days (D56) after application.
[0031] Fig.21 : Ultrasonic scan images of representative skin samples taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the night moisturizer composition of Example 3.
[0032] Fig. 22 : High resolution images showing improvement in skin appearance taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the nighttime moisturizer composition of Example 3.
[0033] Fig.23 : Wrinkle depth images showing reduction in wrinkle depth of a representative subject taken before (D0) and after 28 days (D28) and 56 days (D56) of application of the nighttime moisturizer composition of Example 3.
[0034] Fig.24 : Subjective feelings of subjects at 28 days (D28) and 56 days (D56) after using the night moisturizer composition of Example 3.
[0035] Fig.25 : Punch biopsy images of polyphenol-stained skin treated with a solution of pentagallic glucosyl ester (in dimethyl isosorbide) (applied for 24 days) compared to untreated skin from the same subject. Left image is skin treated with a solution of pentagallic glucosyl ester; right image is untreated skin.
[0036] Fig.26 : Punch biopsy images of VVG-stained skin treated with a solution of pentagallic glucosyl ester (in dimethyl isosorbide) (applied for 24 days) compared to untreated skin from the same subject. The left image is skin treated with a solution of pentagallic glucosyl ester; the right image is untreated skin. Elastin appears as black fibers in the image. DETAILED DESCRIPTION
[0037] Human skin consists of three layers of tissue. The outer layer, called the epidermis, provides a barrier to environmental pathogens, regulates the amount of water released by the body, and provides mechanical resistance to minor injuries. The dermis is the thickest layer of the skin and lies beneath the epidermis. The dermis is primarily composed of dense, irregular connective tissue that cushions the body from stress and strain. The structural components of the dermis include collagen, elastic fibers composed of elastin, and a fibrous extracellular matrix. Elastin is a key protein component of the skin's connective tissue and affects skin elasticity. Aging and environmental processes can degrade the elastin component of the dermis, leading to a loss of elasticity and firmness and the formation of wrinkles as the skin ages.
[0038] In various embodiments, the composition of the present disclosure is a topical composition comprising pentagallic acid glucosyl ester. When properly formulated to allow an effective amount of pentagallic acid glucosyl ester to penetrate through the epidermis and enter the dermis of the skin, pentagallic acid glucosyl ester can bind to elastin, thereby stabilizing elastin and reducing degradation. It also allows tropoelastin secreted by cells to anchor and remain in the skin. As a result, the elasticity and firmness of the skin are improved.
[0039] Suitable amounts of pentagallic acid glucosyl ester range from about 0.1 wt % to about 2 wt %, including about 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1 wt %, about 1.2 wt %, about 1.4 wt %, about 1.6 wt %, about 1.8 wt % or about 2.0 wt %, including all ranges between any of these values. In a specific embodiment, the amount of pentagallic acid glucosyl ester is about 0.5 wt %.
[0040] Evaluation of topical compositions of glucosyl pentagalyl esters have been shown to increase skin elastin in human skin fibroblast studies and human volunteer studies. In vivo animal studies have shown a reduction in skin inflammation, and cell culture studies have demonstrated a reduction or prevention of free radical damage.
[0041] Gallic tannins other than pentagallocitrate glucosyl esters may also be used in the compositions of the present invention, for example digallocitrate glucoses, such as 1,6-digallocitrate glucose, 2,6-digallocitrate glucose and 3,6-digallocitrate glucose; trigallocitrate glucoses, such as 1,2,3-trigallocitrate glucose, 1,2,6-trigallocitrate glucose and 1,3,6-trigallocitrate glucose; tetragallocitrate glucoses, such as 1,2,3,6 tetragallocitrate glucose and 1,2,4,6 tetragallocitrate glucose; hexagallocitrate glucose, heptagallocitrate glucose, octagallocitrate glucose, nonagitrate glucose and decagallocitrate glucose. Other polyphenolic compounds are also suitable for the compositions of the present disclosure, particularly polyphenols containing at least four phenolic groups. A non-limiting list of such classes of compounds includes flavonoids (such as flavonoids (e.g., flavonols, isoflavones, flavones, flavanones and flavanols)), non-flavonoids, phenolic acids and anthocyanidins. Specific compounds include resveratrol, lignans, quercetin, daidzein, apigenin, naringenin, catechins, gallic acid, combinations thereof, and derivatives thereof.
[0042] It can be difficult to incorporate pentagalloylglucosyl esters or other polyphenols as described herein into compositions of the present disclosure, particularly creams or lotions, because pentagalloylglucosyl esters (and other polyphenols) are not highly soluble in water or conventional cosmetic excipients. Therefore, it must be dissolved in a cosmetically acceptable solvent. Such cosmetically acceptable solvents may include dimethyl isosorbide, dimethyl sulfoxide (DMSO), dimethylacetamide, ethanol, propanol, and fatty alcohols (such as cetyl alcohol, stearyl alcohol, cetearyl alcohol, lanolin alcohol, and combinations thereof).
[0043] In other embodiments, the composition of the present disclosure also includes one or more low molecular weight hyaluronic acid (HA). Hyaluronic acid is a hydrophilic, anionic, non-sulfated glycosaminoglycan widely distributed in connective tissue. The production of HA in the skin decreases with age, and the reduction of HA levels in the skin causes very little skin moisture content, resulting in thinner skin and more wrinkles. In various embodiments, the composition of the present disclosure includes two forms of HA, "micro HA" and "small HA". Micro HA is a hydrolyzed sodium hyaluronate formed by fermentation of Lactobacillus plantarum as described in EP 3730623 (for all purposes, incorporated herein by reference as a whole), and the accession number is CGMCCNo.16836, providing a low molecular weight hyaluronic acid with a molecular weight of about 1kDa to 60kDa, more specifically less than 5000Da. Micro HA can be obtained from Bloomage BioTech. Small HA is an oligomeric sodium hyaluronate with a molecular weight less than 10kDA, which can also be obtained from Bloomage BioTech. In alternative embodiments, low molecular weight hyaluronic acid of the present disclosure has a molecular weight that can penetrate the skin. Generally, the molecular weight greater than about 10kDa is not easy to penetrate the skin, so in specific embodiments, the hyaluronic acid of the present invention comprises at least a portion of the molecular weight lower than about 10kDa. It should be understood in the art that hyaluronic acid is usually characterized by mean molecular weight or molecular weight distribution (such as characterized by some other parameters of its polydispersity or limiting molecular weight distribution). Therefore, even if the mean molecular weight of hyaluronic acid is higher than about 10kDa, the part of hyaluronic acid molecular weight distribution lower than 10kDa will also penetrate the skin, and the part higher than 10kDa will provide good skin feel for the skin surface. Therefore, even the hyaluronic acid with mean molecular weight higher than 10kDa is also suitable for compositions as described herein.
[0044] Without being bound by theory, the combination of low molecular weight hyaluronic acid and polyphenol (such as pentagallic acid glucosyl ester) effectively increases the amount of elastin in the skin.Low molecular weight hyaluronic acid increases the amount of tropoelastin (soluble precursor of elastin) produced by skin cells.As such, the increase in the production of tropoelastin produced by applying low molecular weight hyaluronic acid to the skin will not lead to higher levels of elastin, because tropoelastin will not remain in situ, and is eventually eliminated, particularly in old skin (it has a reduced level of glycoprotein (such as fibrillin)).When low molecular weight hyaluronic acid is combined with polyphenol (such as pentagallic acid glucosyl ester), polyphenol (such as pentagallic acid glucosyl ester) "anchors" tropoelastin in situ, so that they can be cross-linked and form elastin fibers in the skin.
[0045] Based on cell culture studies, micro-HA inhibits the release of inflammatory cytokines (TNF-α, IL-1α and IL-6) from UV-treated keratinocytes, scavenges free radicals, repairs UV damage to fibroblasts and keratinocytes, promotes keratinocyte proliferation and enhances the barrier function of the skin.
[0046] Small HA is easily absorbed into the skin and has been shown in in vitro skin tests to penetrate at levels of 36.2%, 60.7% and 69.5% at 1h, 8h and 24h after application, respectively. Small HA has been shown to provide deep moisturizing, promote the repair of damaged cells, scavenge free radicals, improve skin elasticity and reduce wrinkle depth, just like micro HA.
[0047] The amount of micro HA ranges from about 0.01 wt % to about 0.1 wt %, including about 0.01 wt %, about 0.02 wt %, about 0.03 wt %, about 0.04 wt %, about 0.05 wt %, about 0.06 wt %, about 0.07 wt %, about 0.08 wt %, about 0.09 wt % or about 0.1 wt %, including all ranges between any of these values. In a specific embodiment, the amount of micro HA is about 0.05 wt %.
[0048] The amount of small HA in the composition of the present disclosure ranges from about 0.05 wt % to about 0.15 wt %, including about 0.05 wt %, about 0.06 wt %, about 0.07 wt %, about 0.08 wt %, about 0.09 wt %, about 0.1 wt %, about 0.11 wt %, about 0.12 wt %, about 0.13 wt %, about 0.14 wt %, or about 0.15 wt %, including all ranges between any of these values. In a specific embodiment, the amount of small HA is about 0.1 wt %.
[0049] In a specific embodiment, the composition of the present disclosure comprises about 0.1% to about 1% by weight of pentagallic acid glucosyl ester and about 0.01% to about 0.15% by weight of one or more hyaluronic acids independently having a molecular weight of less than about 10 kDa. In a more specific embodiment, the composition of the present disclosure comprises about 0.1% to about 1% by weight of pentagallic acid glucosyl ester, about 0.01% to about 0.1% by weight of micro-HA, and about 0.05% to about 0.15% by weight of small-sized HA. In yet a more specific embodiment, the composition of the present disclosure comprises about 0.5% by weight of pentagallic acid glucosyl ester, about 0.05% by weight of micro-HA, and about 0.1% by weight of small-sized HA.
[0050] In various embodiments, the compositions of the present disclosure further comprise a peptide, such as Akiralin Peptide Solution C) (Acetyl Hexapeptide-3, Acetyl Hexapeptide-8. Akiralin Peptide Solution C has the effect of reducing or preventing / slowing down the formation of wrinkles. This is believed to be achieved by reducing the release of catecholamines (epinephrine and norepinephrine); excessive production of such catecholamines is associated with the formation of fine lines and wrinkles. Clinical studies have shown that wrinkles around the eyes are reduced by up to 10% after 15 days of application and up to 27% after 30 days of application.
[0051] In various embodiments, the compositions of the present disclosure further comprise Aquaxyl (INCI name: Xylitol Glucoside-Anhydroxylitol-Xylitol). Aquaxyl is a complex of natural sugar derivatives. It helps dehydrated skin by acting on three key mechanisms of natural hydration: strengthening the skin barrier by stimulating ceramide synthesis, optimizing water reserves by increasing the levels of natural moisturizing factor and hyaluronic acid in the skin; and acting on aquaporins to increase the water content in the epidermis. When present, the amount of Aquaxyl ranges from about 0.1% by weight to about 1% by weight, including about 0.1% by weight, about 0.2% by weight, about 0.3% by weight, about 0.4% by weight, about 0.5% by weight, about 0.6% by weight, about 0.7% by weight, about 0.8% by weight, about 0.9% by weight, or about 1% by weight, including all ranges between any of these values. In a specific embodiment, the amount of Aquaxyl is about 0.6% by weight.
[0052] In various embodiments, the compositions of the present disclosure further comprise Ectoin. Ectoin is an amino acid derivative obtained by fermentation. Ectoin is a long-lasting moisturizer that repairs damage to skin cells caused by ultraviolet rays, promotes the production of collagen, and resists aging by increasing the stress resistance of skin cells.
[0053] In various embodiments, the compositions of the present disclosure further comprise Equibiome (INCI name: Propylene glycol-Aqua / water-Arctium lappa root extract). Equibiome is obtained from the root of the burdock plant. It improves the overall skin barrier by increasing epidermal cohesion and resistance and reduces excessive pro-inflammatory responses to skin microorganisms.
[0054] In various embodiments, the compositions of the present disclosure further comprise Matrixyl 3000 (palmitoyl oligopeptide, palmitoyl tetrapeptide-3). Matrixyl 3000 is commercially available from Sederma. Matrixyl 3000 acts synergistically with the other components of the compositions of the present disclosure and has been shown to enhance collagen and elastin production.
[0055] Various classes of peptides, such as peptides that act as enzyme inhibitors, signal peptides, structural peptides, and neurotransmitter-inhibitor peptides may also be used in the compositions of the present disclosure. Examples of signal peptides include copper tripeptide-1 (also known as GHK-Cu or ), Biopeptide-CL (Pal-GHK), palmitoyl tripeptide-3 / 5, hexapeptide (peptamide-6) (FVAPFP or phenylalanine-valine-alanine-proline-phenylalanine-proline), acetyl tetrapeptide-9 (AcTP1), acetyl tetrapeptide-11 (AcTP2), Pal-KTTKS (palmitoyl pentapeptide-4 or palmitoyl pentapeptide-3 or palmitoyl oligopeptide or ), tripeptide-10 citrulline (decorinyl tetrapeptide or Decorinyl TM ), human growth hormone, TGF-α, TGF-β, IFN-α, Hsp70 and aquaporin. Examples of neurotransmitter inhibitor peptides include acetyl hexapeptide-3 ( or acetyl hexapeptide-8), pentapeptide-18 Pentapeptide-3 and -Ake (tripeptide-3 or dipeptide diaminobutyryl benzamide diacetate). Enzyme inhibitor peptides suitable for the compositions of the present disclosure include soy protein / amino acids (wild soybean protein or Examples of structural proteins suitable for use in the compositions of the present disclosure include keratin / amino acids. ) and silk protein.
[0056] In various embodiments, the compositions of the present disclosure further comprise Novemer EC-2 polymer. Novemer EC-2 polymer is a versatile emulsifier. It can be used in both hot and cold manufacturing processes and provides an elegant sensory experience (spreading, layering effect, beautiful after-feel).
[0057] In various embodiments, the compositions of the present disclosure further comprise Phytocream 2000: (INCI name: potassium palmitoyl hydrolyzed wheat protein, glyceryl stearate and cetearyl alcohol). Phytocream 2000 is a nonionic emulsifier, particularly for oil-in-water emulsions. Its lipid fraction is compatible with the stratum corneum and helps restore the structural balance of the natural lipid membrane, which strengthens the protective barrier of the skin.
[0058] In various embodiments, the compositions of the present disclosure further comprise potassium cetyl phosphate (eg, Colafax CPE-K). Potassium cetyl phosphate is a water-soluble emulsifier designed to function as a co-emulsifier, surfactant, and emulsifier.
[0059] In yet other embodiments, the compositions of the present disclosure further comprise amino acids that promote collagen production, such as gamma-aminobutyric acid (GABA), lysine, glycine, and proline. GABA has been shown to reduce skin wrinkle depth, promote proliferation of both fibroblasts and keratinocytes, increase the synthesis of collagen and hyaluronic acid in the skin, and improve skin elasticity by up to 10%.
[0060] Other additives that promote collagen formation include retinoic acid and vitamin C (including ascorbic acid and its salts and / or derivatives such as magnesium 1-ascorbic acid 2-phosphate, sodium 1-ascorbic acid 2-phosphate, 1-ascorbic acid 2-glucoside and 1-ascorbic acid ethyl ester.
[0061] The amount of GABA in the compositions of the present disclosure ranges from about 0.01% by weight to about 0.1% by weight, including about 0.01% by weight, about 0.02% by weight, about 0.03% by weight, about 0.04% by weight, about 0.05% by weight, about 0.06% by weight, about 0.07% by weight, about 0.08% by weight, about 0.09% by weight or about 0.1% by weight, including all ranges before any of these values. In a specific embodiment, the amount of GABA is about 0.05% by weight.
[0062] In a specific embodiment, the composition of the present disclosure comprises about 0.1% by weight to about 1% by weight of five gallic acid glucosyl esters, about 0.01% by weight to about 0.15% by weight of one or more hyaluronic acids independently having a molecular weight of less than about 10kDa, and about 0.01% by weight to about 0.1% by weight of amino acids (such as GABA) that promote collagen production. In a more specific embodiment, the composition of the present disclosure comprises about 0.1% by weight to about 1% by weight of five gallic acid glucosyl esters, about 0.01% by weight to about 0.1% by weight of micro HA, about 0.05% by weight to about 0.15% by weight of small HA, and about 0.01% by weight to about 0.1% by weight of GABA. In a more specific embodiment, the composition of the present disclosure comprises about 0.5% by weight of five gallic acid glucosyl esters, about 0.05% by weight of micro HA, about 0.1% by weight of small HA, and about 0.05% by weight of GABA.
[0063] In yet other embodiments, the compositions of the present disclosure also include ectoine. Ecdoine is 1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid, a natural compound found in several bacteria. Ecdoine acts as an osmotic agent and can protect cells from osmotic stress. In in vitro tests on human cells, ectoine has been shown to prevent cell damage from ultraviolet and visible light, prevent cell stress, inhibit the release of inflammatory factors and promote the synthesis of collagen.
[0064] When present, the range of the amount of Ecdoin in the composition of the present disclosure is from about 0.05 wt % to about 0.15 wt %, including about 0.05 wt %, about 0.06 wt %, about 0.07 wt %, about 0.08 wt %, about 0.09 wt %, about 0.1 wt %, about 0.11 wt %, about 0.12 wt %, about 0.13 wt %, about 0.14 wt % or about 0.15 wt %, including all ranges before any of these values. In a specific embodiment, the amount of Ecdoin is about 0.1 wt %.
[0065] In certain embodiments, such as compositions for the face and neck, the compositions of the present disclosure further comprise Aquaxyl, which is a mixture of xylitol glucoside, anhydroxylitol, and xylitol. Aquaxyl reduces skin water loss and enhances the moisturizing efficiency of glycerol.
[0066] When present, the amount of Aquaxyl ranges from about 0.1 wt % to about 1.1 wt %, including about 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1.0 wt % or about 1.2 wt %, including all ranges between any of these values. In a specific embodiment, the amount of Aquaxyl is about 0.6 wt %.
[0067] In certain embodiments, such as compositions for the face and neck, the compositions of the present disclosure further comprise Equibiome, which is a mixture of water, propylene glycol, and burdock root extract. Equibiome has been shown to reduce or prevent biofilms of Staphylococcus aureus (S. aureus), increase the skin's barrier to bacteria, and improve moisturization.
[0068] When present, the amount of Equibiome ranges from about 0.1 wt % to about 1.1 wt %, including about 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1.0 wt %, or about 1.2 wt %, including all ranges between any of these values. In a specific embodiment, the amount of Equibiome is about 0.6 wt %.
[0069] In certain embodiments, such as compositions for the face and neck, the compositions of the present disclosure further comprise Fluidpure, which is a mixture of hexylene glycol, capryloyl glycine, and xylitol glucoside. Fluidpure reduces irritation and can act as a deodorant by reducing odor.
[0070] When present, the amount of Fluidpure ranges from about 0.3 wt % to about 1.3 wt %, including about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, about 0.9 wt %, about 1.0 wt %, about 1.1 wt %, about 1.2 wt %, or about 1.3 wt %, including all ranges between any of these values. In a specific embodiment, the amount of Fluidpure is about 0.8 wt %.
[0071] In certain embodiments, such as compositions for the face and neck, the compositions of the present disclosure further comprise Matrixyl 3000, which is a mixture of water, pentylene glycol, caprylyl glycol, N-propyl palmitoyl tripeptide. Matrixyl 3000 has been shown to increase collagen production in in vitro cell cultures and reduce wrinkles.
[0072] When present, the amount of Matrixyl 3000 ranges from about 2 wt % to about 4 wt %, including about 2.0 wt %, about 2.2 wt %, about 2.4 wt %, about 2.6 wt %, about 2.8 wt %, about 3.0 wt %, about 3.2 wt %, about 3.4 wt %, about 3.6 wt %, about 3.8 wt % or about 4.0 wt %, including all ranges between any of these values. In a specific embodiment, the amount of Matrixyl 3000 is about 2.0 wt %.
[0073] In certain embodiments, such as compositions for nighttime moisturization, the compositions of the present disclosure further comprise Akiralin Peptide Solution C, which is a mixture of acetyl hexapeptide-8 and caprylyl glycol. Akiralin Peptide Solution C has been shown to relax muscle contractions, inhibit glutamate release, which slows wrinkle activity and reduces wrinkle volume, length, and depth.
[0074] When present, the amount of Akiralin peptide solution C ranges from about 2.5 wt % to about 7.5 wt %, including about 2.5 wt %, about 2.7 wt %, about 2.9 wt %, about 3.1 wt %, about 3.3 wt %, about 3.5 wt %, about 3.7 wt %, about 3.9 wt %, about 4.1 wt %, about 4.3 wt %, about 4.5 wt %, about 4.7 wt %, about 4.9 wt %, about 5.1 wt %, about 5.3 wt %, about 5.5 wt %, about 5.7 wt %, about 5.9 wt %, about 6.1 wt %, about 6.3 wt %, about 6.5 wt %, about 6.7 wt %, about 6.9 wt %, about 7.1 wt %, about 7.3 wt %, or about 7.5 wt %, including all ranges between any of these values. In a specific embodiment, the amount of Akiralin peptide solution C is about 5.0 wt %.
[0075] In a specific embodiment, such as a composition of the present disclosure formulated as an eye cream, the composition further comprises "Eyeliss", which is a mixture of water, glycerin, methyl hesperidin chalcone, steareth-20, dipeptide-2, and palmitoyl tetrapeptide-7. Eyeliss has been shown to improve lymphatic circulation, improve capillary fragility, and effectively reduce swelling of the skin around the eyes and reduce eye bags.
[0076] In such compositions, the amount of eyelid peptide ranges from about 1.5 wt % to about 2.5 wt %, including about 1.5 wt %, about 1.6 wt %, about 1.7 wt %, about 1.8 wt %, about 1.9 wt %, about 2.0 wt %, about 2.1 wt %, about 2.2 wt %, about 2.3 wt %, about 2.4 wt % or about 2.5 wt %, including all ranges between any of these values.
[0077] In a specific embodiment, the composition of the present disclosure comprises pentagallic glucosyl ester, hydrolyzed sodium hyaluronate and aminobutyric acid. In a specific embodiment, the composition of the present disclosure comprises pentagallic glucosyl ester, hydrolyzed sodium hyaluronate and aminobutyric acid, wherein the hydrolyzed sodium hyaluronate is a mixture of at least two different grades of hydrolyzed sodium hyaluronate, such as one having a molecular weight ranging from about 1 kDa to 60 kDa and another having a molecular weight of less than 10 kDa. In a more specific embodiment, the hydrolyzed sodium hyaluronate polymer comprises a mixture of micro-HA and small-HA as described herein.
[0078] In various embodiments, the compositions of the present disclosure further comprise additional cosmetically acceptable ingredients selected from the group consisting of fragrances, dyes, colorants, adsorbents, lubricants, solvents, moisturizers (emollients, humectants, film formers, occlusive agents), hydrophobic agents, UV absorbers (physical absorbers such as titanium dioxide, zinc oxide, etc.; chemical absorbers such as para-aminobenzoic acid (PABA) and PABA derivatives), essential oils, vitamins (e.g., A, B, C, D, E, and K), trace metals (e.g., zinc, calcium, and selenium), anti-irritants (e.g., steroids and nonsteroidal anti-inflammatory drugs), plant extracts (e.g., aloe, chamomile, cucumber extract, ginkgo, ginseng, and rosemary), antimicrobial agents, antioxidants (e.g., BHT and tocopherol), chelating agents (e.g., disodium EDTA and tetrasodium EDTA), preservatives (e.g., methylparaben and The invention also includes but is not limited to: 1) a skin lightening agent (e.g., propylparaben), 2) a pH adjusting agent (e.g., sodium hydroxide and citric acid), 3) an absorbent (e.g., aluminum starch octenylsuccinate, kaolin, corn starch, oat starch, cyclodextrins, talc and zeolite), 4) a skin whitening and lightening agent (e.g., hydroquinone and niacinamide lactate), 5) a humectant (e.g., sorbitol, urea and mannitol), 6) an exfoliant, 7) a water repellent (e.g., aluminum hydroxide / magnesium stearate) and 8) a skin conditioning agent (e.g., aloe extract, allantoin, bisabolol, ceramides, dimethicone, hyaluronic acid and dipotassium glycyrrhizinate).
[0079] Suitable fragrances for cosmetics suitable for the compositions of the present disclosure include, for example, natural or synthetic odorants or mixtures thereof, which produce attractive odors alone or in combination. Non-limiting examples of natural odorants include extracts of flowers (lily, lavender, rose, jasmine, orange blossom or ylang-ylang), stems and leaves (geranium, patchouli, orange leaf), fruits (fennel, coriander, caraway, juniper), peels (bergamot, lemon, orange), roots (macmead, angelica, celery, cardamom, costus, iris, thyme), needles and twigs (spruce, fir, pine, mountain pine) and resins and balsams (galbanum, elemi, benzoin, myrrh, frankincense, opoponax). Typical synthetic fragrance compounds include esters, ethers, aldehydes, ketones, alcohols and hydrocarbons. Low volatility essential oils commonly used as flavoring components are also suitable for use as fragrances, such as, but not limited to, sage oil, chamomile oil, clove oil, melissa oil, peppermint oil, cinnamon leaf oil, linden blossom oil, juniper berry oil, vetiver oil, frankincense oil, galbanum oil, labdanum oil, and lavandin oil.
[0080] A non-limiting list of cosmetically suitable moisturizers includes petrolatum, lanolin, mineral oil, dimethicone (silicone fluid), cetyl alcohol, cetearyl alcohol, cocoa butter, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, diisopropyl adipate, diisopropyl sebacate, lanolin, liquid paraffin, shea butter, silicone oil, stearic acid, stearyl alcohol, castor oil, glycerin, lecithin, propylene glycol, and ethylene glycol.
[0081] Non-limiting examples of cosmetically acceptable emulsifiers include polyglyeryl-based emulsifiers, polyol esters, glycerol ethers, oxyethylenated and / or oxypropylenated ethers, glycol polymers, sorbitan esters, nonionic or surfactant-type emulsifiers, such as alkanolamides; alkyl polyglucosides; polyoxyethylenated nonionic surfactants; polyglycerolated nonionic surfactants; ethoxylated fatty esters; ethoxylated, propoxylated or glycerolated alcohols, α-diols, alkylphenols and fatty acid esters; copolymers of ethylene oxide and / or propylene oxide; condensates of ethylene oxide and / or propylene oxide with fatty alcohols; polyethoxylated fatty amides; ethoxylated fatty acid esters of sorbitan containing 2 to 30 mol of ethylene oxide; ethoxylated oils of vegetable origin; sucrose fatty acid esters; polyethylene glycol fatty acid esters; glycerol (C6-C 24 ) polyethoxylated fatty acid monoester or diester of alkyl glycoside; N-(C6-C 24 ) alkyl glucosamine derivatives, amine oxides such as (C 10 -C 14 ) alkylamine oxide or N-(C 10 -C 14 )amidopropylmorpholineoxide; and mixtures thereof.
[0082] The pH of the cosmetic composition of the present disclosure may be from about 4 to about 12, including 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 or 12, including any pH range between any of these values. The pH of the composition of the present disclosure may be adjusted to a desired value using at least one acidulant or base as is well known in the art.
[0083] The cosmetic composition of the present disclosure is generally in the form of an emulsion. The emulsion of the present disclosure may be an oil-in-water emulsion, a water-in-oil emulsion, a water-in-oil-in-water emulsion, an oil-in-water-in-oil emulsion, etc. The composition of the present disclosure may also include a suspension or a solution.
[0084] When applied to the skin in cosmetically appropriate amounts, the compositions of the present disclosure improve the elasticity and firmness of the skin.
[0085] The compositions of the present disclosure are typically applied to the skin daily, but in alternative embodiments, twice or more per day (e.g., morning and evening). The amount applied may range from about 0.5 / cm 2 About 10g / cm 2 , including about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9 or about 10 g / cm 2 , including any range between any of these values. Applying to the skin means placing a certain amount of the composition of the present disclosure on the skin using, for example, fingers or an applicator, and then evenly applying and spreading the composition on the skin surface to fully absorb or spread as a thin layer on the skin.
[0086] The compositions of the present disclosure formulated as nighttime moisturizers include emollients such as fatty acid esters, isopropyl isostearate, Phytocream 2000 (a mixture of potassium palmitoyl hydrolyzed wheat protein, glyceryl stearate, and cetearyl alcohol), diisopropyl adipate, diisopropyl sebacate, silicone oils, and the like; and film formers such as Xpertmoist Molecular Film (INCI Name: Water (or Aqua), Glycerin, Pseudoalteromonas Ferment Extract, Xanthan Gum, Proline, Alanine, Serine, Sodium Phosphate, Sodium Hydroxide, Tocopherol, Caprylyl Glycol, Ethylhexylglycerin), Actimoist Bio-1PF (INCI Name: Water (and) Sodium Hyaluronate), and November EC-2 Polymer (INCI Name: Sodium Acrylates / Beheneth-25 Methacrylate Crosspolymer (and) Hydrogenated Polydecene (and) Lauryl Glucoside).
[0087] When taken at least daily in the range of 0.5–10 g / cm 2 When the amount of the composition of the present disclosure is applied to the skin, the composition provides one or more of improved firmness, skin thickness, elasticity, increased hydration, reduced roughness or reduced wrinkle depth. The range of the amount of improvement is at least about 5% to about 100% or more at most, including about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 80%, about 90%, about 95% or about 100%, including any range between any of these values. Improvement can be measured using methods known in the art for measuring changes in skin firmness, skin thickness, elasticity, hydration, roughness or wrinkle depth (including methods disclosed herein).
[0088] Example
[0089] Example 1: Face and Neck Firming Gel Essence
[0090] A face and neck firming serum was prepared having the following composition shown in Table A:
[0091] Table A
[0092]
[0093] 1. Homogenize phase A at room temperature.
[0094] 2. Gently stir to mix phase B at room temperature.
[0095] 3. For phase C:
[0096] a. Dissolve glucosyl pentagallate in one or more cosmetically acceptable solvents.
[0097] b. Separately mix together the remaining Phase C ingredients until a homogeneous mixture is obtained.
[0098] c. Add b to a while stirring continuously.
[0099] 4. Separately mix together Phase D ingredients 18-21 until a homogeneous mixture is obtained.
[0100] 5. Add phases B, C and D very slowly to phase A while stirring until a more viscous and homogeneous gel is obtained.
[0101] 6. Fill the batch into suitable containers and store the batch at room temperature.
[0102] Example 2: Firming Eye Cream
[0103] A firming eye cream was prepared having the following composition shown in Table B:
[0104] Table B
[0105]
[0106] 1. Mix the Phase A ingredients together with stirring and heating to form a uniform mixture.
[0107] 2. Add Phase B ingredients one at a time to Phase A. Mix after each addition until smooth.
[0108] 3. While heating, add the Phase C ingredients one at a time to the mixture of Phases A and B and mix until uniform.
[0109] 4. Add Phase D ingredients one at a time to the Phase AC mixture, mixing thoroughly between each addition.
[0110] 5. Mix the Phase E ingredients together separately to form a uniform mixture, and then add to the Phase AD mixture with stirring to form a uniform mixture.
[0111] Example 3: Hydrating Night Moisturizer
[0112] A hydrating night moisturizer was prepared having the following composition shown in Table C:
[0113] Table C
[0114]
[0115] 1. Mix the glucosyl pentagallate and solvent to form a uniform mixture. Mix the remaining ingredients in phase A to form a uniform mixture. Slowly add the glucosyl pentagallate solution to the mixture of phase A ingredients to form a uniform mixture.
[0116] 2. In a separate container, mix the Phase B ingredients under heat until homogeneous, then add to the Phase A mixture.
[0117] 3. Add the ingredients of phase C to the mixture of phases AB in sequence, mixing thoroughly between each addition.
[0118] 4. Adjust the pH to about 6.0-6.5 using the pH control agent in Phase D.
[0119] Example 4: Insoluble Elastin Production
[0120] Human dermal fibroblasts (CCD-1064sk( CRL-2076TM)) were cultured at a seeding density of 200,000 cells / well (12-well plate) and incubated with 0.05% Neolastin dissolved in dimethyl isosorbide (DMI) in a humidified atmosphere of 37°C and 5% CO2. As a control, cells were also exposed to DMI without Neolastin. Four replicates were prepared. Negative controls did not contain DMI or Neolastin. After 14 days of culture, cells cultured in the presence of 0.05 Neolastin showed a significant increase in the production of insoluble elastin. See Figure 1A -1C. This suggests that a cosmetic composition comprising glucosyl pentagallate can stimulate the production of insoluble elastin in the skin, thereby improving skin firmness and appearance.
[0121] Example 5: Neck Firming Cream
[0122] The neck firming cream described in Example 1 was tested on human subjects. After 28 and 56 days of application, the subjects' skin roughness was reduced by an average of 12% and 20%, respectively. Figure 2 , where the lower R a Values indicate lower roughness. The percentage of subjects reporting improved perceived roughness was 82% at 28 days and 94% at 56 days. Figure 3 After 28 days, skin firmness increased by an average of 11%. Figure 4 , where a high F2 value indicates a higher firmness. Skin hydration increased by an average of 9% after 24 hours and 56 days (long-term hydration).
[0123] Ultrasound scans of the subjects' skin taken at the beginning (D0), at 28 days (D28) and at 56 days (D56) after treatment with the neck firming cream showed improvements in skin structure, as shown in Figure 2. Figure 5 High-resolution photos of wrinkles of test subjects taken at the initial stage (D0), at 28 days (D28) and at 56 days (D56) ( Figure 6 and Figure 7 ) showed a reduction in the appearance of fine lines and wrinkles.
[0124] Overall, after 56 days, 97% of test subjects noticed smoother, healthier skin; 94% felt their skin was more moisturized, smoother and healthier; 91% felt that the Neck Firming Cream improved skin appearance and texture; 83% noticed that the skin on the face and neckline was firmer and wrinkles looked reduced (filling effect); 80% noticed that the skin was less saggy. Figure 8 .
[0125] Example 6: Eye Cream
[0126] The eye cream described in Example 2 was tested on human subjects. After 28 and 56 days of application, the subjects' skin roughness was reduced by an average of 10% and 9%, respectively. Fig. 9 , where the lower R a Values indicate lower roughness. The percentage of subjects reporting improved perceived roughness was 63% at 28 days and 74% at 56 days. Fig.10 Skin firmness increased by an average of 20% after 28 days and 50% at 56 days, as measured by ultrasound scanning. Fig.11 The percentage of subjects who perceived an improvement in skin density at 28 and 56 days was 52% and 75%, respectively, see Fig.12 . Similar improvements in skin firmness were obtained by the alternative cutometer method. Improvements in skin firmness relative to the control (cosmetic vehicle without glucosyl pentagallate) were noted at 28 and 56 days. See Fig.13 , where lower F4 values indicate higher firmness. Improved skin structure was also observed using ultrasound scan images of representative test subjects before treatment (D0) and after 28 days (D28) or 56 days (D56) of application. See Fig.14 .
[0127] High-definition images of the eye area of representative test subjects before treatment (D0) and after 28 days (D28) or 56 days (D56) of application also showed a reduction in the appearance of fine lines and wrinkles. Figure 15-16 .
[0128] Overall, after 28 days, 97% of test subjects felt their skin was more moisturized, smoother and healthier; 90% felt their skin was more supple; 87% felt their skin was smoother and healthier; and 82% felt the eye cream improved the appearance and texture of their skin. Fig.17 .
[0129] Example 7: Night Moisturizer
[0130] The nighttime moisturizer described in Example 3 was tested on human subjects. After 8 and 24 hours after application, the subjects showed an average increase in skin hydration of 6%. After 28 and 56 days of application, the subjects showed an average decrease in skin roughness of 24% and 20%, respectively. See Fig.18 , where the lower R a Values indicate lower roughness. The percentage of subjects reporting improved perceived roughness was 92% at 28 days and 84% at 56 days. Fig.19 After 56 days of use, subjects showed an average reduction in pigmentation (ie, lower melanin values) of 11%, as measured by melanin reduction. Fig. 20 .
[0131] Improved skin structure was observed using ultrasound scan images of representative test subjects before treatment (D0) and 28 days (D28) or 56 days (D56) after application. Fig.21 .
[0132] High-definition images of the eye area of representative test subjects before treatment (D0) and after 28 days (D28) or 56 days (D56) of application also showed a reduction in the appearance of fine lines and wrinkles. Figure 22-23 .
[0133] Overall, after 28 days, 84% of test subjects felt that the night moisturizer provided intense skin hydration; 82% noticed that skin looked smoother and healthier; and 82% felt their skin was more supple and elastic. Fig.24 .
[0134] Example 8: Histological comparison of polyphenol-stained punch biopsies—treated skin versus untreated skin
[0135] The subjects' left arm was treated with 25% solution of glucosyl pentagallate in dimethyl isosorbide for 2 cm 2 A small area of skin (under the upper arm above the elbow) was then biopsied for 24 days. A biopsy of the treated skin and a similar sample of untreated skin from the right side of the same subject were then taken, sectioned, stained for polyphenols (ferric chloride stain) and imaged using light microscopy. Fig.25 As shown in the left image of , the treated skin exhibited more black staining in the dermis compared to the untreated skin sample (right image), indicating pentaglucosyl pentaglucosyl esters in the dermis and an overall denser tissue.
[0136] Example 9: Histological comparison of elastin (VVG stained) punch biopsies—treated skin versus untreated skin
[0137] The skin of the left arm of the subject was treated with a 25% solution of glucosyl pentagallate in dimethyl isosorbide for 24 days. A biopsy sample of the treated skin and a similar sample of untreated skin from the right side of the same subject were then sectioned and stained for elastic fibers (Verhoeff-Van Gieson, VVG stain which stains elastic fibers black. Fig.26 As shown in the left image, the treated skin exhibited extensive black staining (indicating higher levels of elastin fibers) compared to the untreated skin sample (right image).
Claims
1. A topical composition comprising: a) about 0.2% to 0.6% by weight of glucosyl pentagallate; b) about 0.02 wt % to 0.07 wt % of micro-HA; and c) about 0.05 wt % to 0.15 wt % of small HA; and one or more cosmetically acceptable excipients selected from the group consisting of UV protectants, emollients, humectants, antibacterial agents, emulsifiers, and combinations thereof and c.
2. The topical composition of claim 1 further comprising about 0.02% to 0.07% by weight of aminobutyric acid.
3. The topical composition of claim 1 or 2, wherein 1-10 g / cm is applied daily to the epidermis of a subject. 2 After at least 28 days, the epidermis has improved firmness, elasticity, increased hydration, reduced roughness, or reduced wrinkle depth.
4. A topical composition according to any one of claims 1 to 3 in the form of an oil-in-water emulsion.
5. A topical composition according to any one of claims 1 to 4, comprising: a) about 0.5% by weight of glucosyl pentagallate; b) about 0.05% by weight of aminobutyric acid; c) about 0.05 wt. % micro-HA; and d) about 0.10 wt% of small HA.
6. A method for reducing wrinkles in the epidermal tissue of a subject, comprising administering 1-10 g / cm 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby wrinkles in the epidermis are reduced by at least 5% after at least 28 days of application of the topical composition.
7. A method for increasing the elasticity of epidermal tissue of a subject, comprising: 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby the elasticity of the epidermis is increased by at least 5% after applying the topical composition for at least 28 days.
8. A method for increasing the firmness of epidermal tissue of a subject, comprising administering 1-10 g / cm 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby the firmness of the epidermis is increased by at least 10% after applying the topical composition for at least 28 days.
9. A method for reducing the roughness of epidermal tissue of a subject, comprising: 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby the roughness of the epidermis is reduced by at least 10% after at least 28 days of application of the topical composition.
10. A method for increasing the hydration of epidermal tissue of a subject, comprising: 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby the hydration of the epidermis is increased by at least 5% after applying the topical composition for at least 28 days.
11. A method for increasing the density of epidermal tissue of a subject, comprising: 2 The topical composition of any one of claims 1 to 5 is applied daily in an amount of , whereby the skin density of the epidermis is increased by at least 20% after applying the topical composition for at least 28 days.
Citation Information
Cited By
Composition capable of intervening collagen fibrosis as well as preparation method and application thereof
CN121129889A
